Mark Hendricks, MD
Pulmonary Disease · Macon, GANPI 1306827639
Payments from drug & device makers
Across 393 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Insmed, Inc.$1K
- GSK$1K
- AstraZeneca$826
- Veran Medical Technologies, Inc.$732
- Inspire Medical Systems, Inc.$715
- plus $4K from 33 others
What the payments were for
- Travel & lodging$1,65415%
- Food & beverage$6,73960%
- Education$2,89926%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $2,856 |
| Insmed, Inc. | 78 | $1,317 |
| GSK | 88 | $1,251 |
| AstraZeneca | 40 | $826 |
| Veran Medical Technologies, Inc. | 3 | $732 |
| Inspire Medical Systems, Inc. | 2 | $715 |
| Boehringer Ingelheim | 24 | $477 |
| Sanofi | 13 | $350 |
| Mylan Specialty L.p. | 12 | $231 |
| Actelion Pharmaceuticals US, Inc. | 11 | $217 |
| Amgen | 9 | $178 |
| Merck | 8 | $167 |
| Bayer | 7 | $158 |
| Grifols USA, LLC | 6 | $158 |
| Baxter Healthcare | 8 | $157 |
| Regeneron Healthcare Solutions, Inc. | 5 | $129 |
| United Therapeutics Corporation | 6 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $126 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 9 | $119 |
| Viatris Specialty LLC | 5 | $107 |
| Genentech USA, Inc. | 6 | $96 |
| Harmony Biosciences LLC | 3 | $81 |
| Pfizer | 4 | $80 |
| ANI Pharmaceuticals, Inc. | 4 | $66 |
| Resmed Corp | 4 | $61 |
| Verona Pharma, Inc. | 2 | $59 |
| Johnson & Johnson | 4 | $57 |
| Advanced Respiratory, Inc | 2 | $47 |
| Mallinckrodt Enterprises LLC | 2 | $46 |
| Novartis | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Electromed, Inc. | 1 | $25 |
| Medtronic | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Pulmonx Corporation | 1 | $15 |
| Olympus America Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Inogen, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,732
- Spin$728
- Inspire Upper Airway Stimulation System$687
- XYWAV$125
- TEZSPIRE$104
How this compares
$11,292 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 85 | $1,172,119 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 757 | $608,905 |
| OpsumitMacitentan | 28 | $342,570 |
| AdempasRiociguat | 25 | $327,553 |
| NucalaMepolizumab | 64 | $241,222 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 21 | $182,372 |
| TezspireTezepelumab-Ekko | 34 | $147,481 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 177 | $141,066 |
| Breo ElliptaFluticasone/Vilanterol | 135 | $72,202 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $67,250 |
| Fasenra PenBenralizumab | 11 | $62,105 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $45,051 |
| EliquisApixaban | 42 | $27,483 |
| Spiriva RespimatTiotropium Bromide | 32 | $20,785 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $14,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $477 | $1,237,955174 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,251 | $996,7811,084 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $217 | $342,57028 claims |
| BayerAdempas | $158 | $327,55325 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $826 | $303,467266 claims |
| Grifols USA, LLCProlastin C | $158 | $182,37221 claims |
| PfizerEliquis | $80 | $27,48342 claims |
| MerckBelsomra | $167 | $11,03721 claims |
| Johnson & JohnsonXarelto | $57 | $10,56713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Macon
- Gerald TarirahMacon$38K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.